Quick answer: Psilocybin laws in 2026 changed at the edges rather than at the center. New Jersey funded a hospital psilocybin research pilot, Virginia passed a law that waits for an FDA-approved psilocybin drug, Colorado amended its natural medicine program, and New Mexico began taking permit applications from psilocybin producers. We found no state that legalized or decriminalized psilocybin this year, and no statewide measure to legalize it is on the November 2026 ballot.
None of these changes affects mushroom spores. Spores remain legal in 46 states and restricted or banned in California, Florida, Georgia and Idaho. Everything below is current as of September 26, 2026.
Looking for spore syringes?
We ship Psilocybe cubensis spore syringes the same business day. Each syringe is a 10 cc syringe. Orders over $100 ship free, and our spore syringe packs save you up to 40%.
Intended use and disclaimer. We sell Psilocybe cubensis spore syringes for microscopy, taxonomy and educational use only. This roundup is general information, not legal advice. Every item below was confirmed with two sources, but laws and programs change, so check the current law in your state before relying on it.
In this guide
- Psilocybin laws in 2026 at a glance
- New laws: New Jersey, Virginia and Colorado
- New Mexico’s medical program moves toward launch
- The federal changes behind the state laws
- Psilocybin and the November 2026 ballot
- Bills that failed or stalled
- What the 2026 changes mean for spores
- Frequently asked questions
- Sources
Psilocybin laws in 2026 at a glance
This table lists only changes we could confirm with two independent sources. A bill that was introduced and never moved is not on it.
| State | What happened | When | Status on Sept. 26, 2026 |
|---|---|---|---|
| New Jersey | S2283/A3852 creates a hospital-based psilocybin therapy pilot with $6 million | Signed January 2026 | Law; research only |
| Virginia | HB 1347 and SB 379 set up rescheduling of an FDA-approved psilocybin drug | Signed April 2026 | Law; no effect until FDA approval and federal rescheduling |
| Colorado | HB26-1325 adds an ibogaine research pilot and narrows the personal-use protection | Signed June 4, 2026 | In effect since August 12, 2026 |
| New Mexico | Health department opens producer permit applications under the 2025 Medical Psilocybin Act | August 2026 | Program not yet serving patients |
| Idaho | HJR 4, a constitutional amendment on who may legalize psychoactive substances | Vote on November 3, 2026 | On the ballot |
| Alaska | Psychedelics legalization initiative dropped its 2026 attempt | Announced December 2025 | Aiming for 2028 |
| Illinois | SB 2772 would create a Psilocybin Advisory Board | Passed Senate May 7, 2026 | Stalled in House Rules Committee |
| New Hampshire | HB 1809, amended into a medical psilocybin advisory board bill | Passed House March 26, 2026 | Killed in the Senate in May 2026 |
| Washington | SB 5921 would have created a medical psilocybin program | Referred to Ways and Means February 4, 2026 | Died when the session ended |
New laws: New Jersey, Virginia and Colorado
New Jersey: a hospital research pilot
Governor Phil Murphy signed S2283/A3852 in January 2026. The official chapter law gives the approval date as January 20, and some news reports give January 21. The law creates a psilocybin therapy pilot overseen by an 11-member advisory board and appropriates $6 million for hospital-based research at three hospitals, $2 million each. The Department of Health had 180 days to begin the request-for-proposals process. The law funds research only; it does not legalize or decriminalize psilocybin.
Virginia: a law that waits for the FDA
In April 2026, Governor Abigail Spanberger signed HB 1347 and SB 379. Once the FDA approves a psilocybin formulation to be given by a health care professional in a health care setting, the state Board of Pharmacy must reschedule that formulation, consistent with the federal change, at its next quarterly meeting after the federal scheduling order has been published for 30 days. Until then the law does nothing, and psilocybin remains in Schedule I in Virginia.
Colorado: changes to the natural medicine program
Governor Jared Polis signed HB26-1325 on June 4, 2026, and it took effect on August 12, 2026. The law sets up an ibogaine research pilot with up to five sites, to be paid for with gifts, grants and donations. It also narrows the personal-use protection that Proposition 122 created in 2022: the protection no longer covers people who advertise natural medicine, sell it online, or charge fees for “education” or “harm reduction” while handing out mushrooms. Personal use without payment and the licensed healing centers remain in place. Our Colorado guide covers the details.
New Mexico’s medical program moves toward launch
Governor Michelle Lujan Grisham signed Senate Bill 219, the Medical Psilocybin Act, in April 2025. News reports give the law’s deadline for the program as December 31, 2027 and say the department moved its own target up a year, to serving the first patients by the end of 2026; the department’s program page describes December 31, 2026 as its implementation date. In August 2026 the department opened permit applications for producers who will supply the program. Applications for testing labs and certified clinicians are still to come, and rulemaking is not finished. Qualifying conditions include treatment-resistant depression, PTSD, substance use disorders and end-of-life care. The program is medical only.
The federal changes behind the state laws
Two federal developments form the background to this year’s state activity, much of which prepares for an approved drug rather than changing criminal law.
- The executive order. On April 18, 2026, President Trump signed “Accelerating Medical Treatments for Serious Mental Illness.” It directs the FDA to give priority vouchers to psychedelic drugs with Breakthrough Therapy designation, directs the FDA and DEA to create a Right to Try pathway, and tells the Attorney General to review products containing a Schedule I substance that have completed Phase 3 trials, so that any the FDA approves can be rescheduled quickly. It does not legalize or reschedule psilocybin.
- Compass Pathways’ application. On April 24, 2026, Compass announced that the FDA had agreed to a rolling review of its application for COMP360, a psilocybin drug for treatment-resistant depression, and had awarded it a priority voucher. The company says it will finish the submission in the fourth quarter of 2026. Our post on psilocybin FDA approval follows that process in detail.
Psilocybin and the November 2026 ballot
We found no statewide measure to legalize or decriminalize psilocybin on a November 2026 ballot. Two ballot stories are worth knowing.
- Idaho, HJR 4. Idaho voters will decide on November 3, 2026 whether to amend the state constitution to give the legislature the sole power to legalize marijuana, narcotics or other psychoactive substances. If it passes, citizens could no longer legalize those substances by initiative. It would not change current law on spores, which Idaho already lists in Schedule I.
- Alaska. A campaign to legalize and regulate natural psychedelics tried to qualify for 2026. In December 2025 it announced that it had not gathered enough signatures in time for 2026, and it is now aiming for the 2028 ballot.
Bills that failed or stalled
- Illinois, SB 2772. The bill would create an Illinois Psilocybin Advisory Board to study psilocybin therapy and report to lawmakers. It passed the Senate 41 to 13 on May 7, 2026, and was re-referred to the House Rules Committee on May 15, where it sat when the spring session ended.
- New Hampshire, HB 1809. Introduced as a medical psilocybin program, the bill was amended in the House into a study bill creating an advisory board and passed the House on March 26, 2026. The Senate killed it in May 2026.
- Washington, SB 5921. The bill would have set up a Department of Health program for medical psilocybin prescribed by licensed clinicians. It was referred to the Senate Ways and Means Committee on February 4, 2026, never came out of committee, and was dead by the time the session ended in March.
What the 2026 changes mean for spores
Nothing in this list changes the law on mushroom spores. The new laws deal with research funding, medical programs and what happens after an FDA approval. They leave psilocybin and psilocin where they were in each state’s schedule, and none of them mentions spores. The federal position has not changed either: the DEA’s January 2024 letter treats spores without psilocybin or psilocin as not controlled, as our post on whether mushroom spores contain psilocybin explains.
The four states that restrict spores are the same as last year. Georgia and Idaho ban them, California makes it a crime to cultivate spores with intent to produce psilocybin or to sell or ship them to help someone do that, and Florida has banned selling, shipping and importing them since July 1, 2025. We do not ship to any of the four. For every state’s statute, see our 50-state guide, and for why vendors sell spores the way they do, see why spores are sold for microscopy only.
Frequently asked questions
Did any state legalize psilocybin in 2026?
We found none. The laws passed in 2026 fund research, prepare for an FDA-approved drug, or adjust existing programs. Oregon, Colorado and New Mexico created their programs before 2026.
Is psilocybin on the ballot in November 2026?
We found no statewide measure to legalize or decriminalize psilocybin on a November 2026 ballot. Idaho’s HJR 4 concerns who may legalize psychoactive substances, and Alaska’s psychedelics campaign moved its target to 2028.
What did New Jersey’s 2026 psilocybin law do?
It created a hospital-based psilocybin therapy pilot with $6 million for three hospitals and an 11-member advisory board. It does not legalize or decriminalize psilocybin.
Did Virginia legalize psilocybin in 2026?
No. Virginia’s 2026 law only directs the Board of Pharmacy to reschedule an FDA-approved psilocybin drug after the federal government reschedules it. Psilocybin remains Schedule I in Virginia.
Has the FDA approved psilocybin?
Not as of September 26, 2026. Compass Pathways expects to complete its application for COMP360 in the fourth quarter of 2026.
Did any 2026 law change the legal status of mushroom spores?
No. Spores remain legal in 46 states. The four states that restrict them, California, Florida, Georgia and Idaho, are unchanged.
Sources
- Reason Foundation, State Psychedelics Policy Roundup (March 2026) and MAPS, 2026 First Quarter Legislative Wrap Up
- Marijuana Moment on New Jersey’s pilot law (January 2026)
- Virginia 2026 Acts of Assembly, Chapter 306, Marijuana Moment on the signing and Rouleau Law’s explainer
- Colorado General Assembly, HB26-1325 and Westword on the new law
- Source New Mexico (August 27, 2026), Marijuana Moment on producer permits and New Mexico Department of Health, Medical Psilocybin Program
- Executive Order 14401 in the Federal Register, Morgan Lewis and Harris Sliwoski on the April 18, 2026 executive order
- Compass Pathways (April 24, 2026) and (July 7, 2026)
- Ballotpedia News on 2026 drug-related ballot measures and list of 2026 U.S. ballot measures
- Ballotpedia, Alaska psychedelics initiative (2028) and Marijuana Moment (December 2025)
- Illinois SB 2772 history (LegiScan) and Illinois Senate Democrats (May 7, 2026)
- New Hampshire HB 1809 history (LegiScan), Citizens Count and Marijuana Moment (March 31, 2026)
- Washington SB 5921 status (BillTrack50) and the Washington State Legislature’s bill history
- DEA letter on the federal status of spores (January 2, 2024, PDF)
Psilocybe cubensis spore syringes
Our Psilocybe cubensis spore syringes are 10 cc syringes filled in our ISO-7 cleanroom. Each one comes with a sterile needle. Orders placed by 1 p.m. Eastern on a weekday ship the same day, to the 46 states where spores are legal. You get free shipping on orders over $100, up to 40% off with our 3-, 5- and 10-packs, and a 30-day warranty. They are sold for microscopy and taxonomy use only.
